|Bid||0.00 x 0|
|Ask||519.65 x 0|
|Day's Range||505.00 - 525.00|
|52 Week Range||432.70 - 790.75|
|PE Ratio (TTM)||27.60|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Sun Pharmaceutical Industries Ltd. today announced that one of its wholly owned subsidiaries has received approval from the US Food and Drug Administration for a new label for Odomzo® , an oral hedgehog inhibitor indicated for the treatment of patients with locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or ...
To access the newsletter, click on the link: http://share.thomsonreuters.com/assets/newsletters/Indiamorning/MNC_IN_08142017.pdf If you would like to receive this newsletter via email, please register ...
The billionaire founder of Sun Pharmaceutical Industries Ltd. pledged that the drugmaker would do better after reporting its first loss in at least 12 years amid regulatory headaches and a weakening market ...